Vincristine-d3 is a deuterated derivative of vincristine, a well-known chemotherapeutic agent derived from the periwinkle plant, Catharanthus roseus. This compound is primarily used in the treatment of various cancers, including leukemia and lymphomas. The "d3" designation indicates that three hydrogen atoms in the vincristine molecule have been replaced with deuterium, a stable isotope of hydrogen. This modification can enhance the compound's stability and alter its pharmacokinetic properties, making it useful for research purposes, particularly in studies involving drug metabolism and pharmacodynamics. Vincristine-d3 retains the core structure and biological activity of vincristine, which includes its ability to inhibit microtubule formation, thereby disrupting mitosis in cancer cells. The compound is typically characterized by its molecular weight, solubility in organic solvents, and specific spectral properties, such as NMR and mass spectrometry, which help confirm its identity and purity in laboratory settings. As with all chemotherapeutic agents, vincristine-d3 is handled with care due to its potent biological effects and potential toxicity.

Vincristine-d3 is intended for use as an internal standard for the quantification of vincristine (Item No. 11764) by GC- or LC-MS. Vincristine is a vinca alkaloid that has been found in C. rosea and has anticancer activities.1,2 It inhibits tubulin polymerization in a cell-free assay (Ki = 0.085 µM) and induces mitotic arrest in U937 cells when used at a concentration of 10 nM. In vivo, vincristine (3 mg/kg) reduces tumor growth in rhabdomyosarcoma patient-derived xenograft (PDX) mouse models.3 Formulations containing vincristine have been used in the treatment of various cancers.WARNING This product is not for human or veterinary use.

Vincristine-d3

1246817-09-3: Vincristine-d3 is a deuterated derivative of vincristine, a well-known chemotherapeutic agent derived from the periwinkle plant, Catharanthus roseus. This compound is primarily used in the treatment of various cancers, including leukemia and lymphomas. The "d3" designation indicates that three hydrogen atoms in the vincristine molecule have been replaced with deuterium, a stable isotope of hydrogen. This modification can enhance the compound's stability and alter its pharmacokinetic properties, making it useful for research purposes, particularly in studies involving drug metabolism and pharmacodynamics. Vincristine-d3 retains the core structure and biological activity of vincristine, which includes its ability to inhibit microtubule formation, thereby disrupting mitosis in cancer cells. The compound is typically characterized by its molecular weight, solubility in organic solvents, and specific spectral properties, such as NMR and mass spectrometry, which help confirm its identity and purity in laboratory settings. As with all chemotherapeutic agents, vincristine-d3 is handled with care due to its potent biological effects and potential toxicity.

CAS 1246817-09-3

Vincristine-d3

Vincristine-d3

Ref: 4Z-V-1914